India's biotech push reaches an inflection point, but funding remains the missing piece

India's biotech sector is shifting towards innovation, but funding is a hurdle. Leaders say "the availability of long-term growth capital remains the biggest hurdle." While early support improved, startups need more funds for development and scale-up. Many companies previously used acquisitions for growth but now focus on innovation.